Medopa (Dopamine Hydrochloride)

Dopamine stimulates dopaminergic (D1), beta‑1 adrenergic, and alpha‑adrenergic receptors. Low doses cause renal vasodilation, moderate doses increase heart contractility, and high doses produce vasoconstriction, allowing dose‑dependent cardiovascular support.

The appropriate dose of Medopa is determined by the prescribing clinician based on the patient’s condition, response, and monitoring parameters. Dosing is individualized and adjusted during infusion.

Safety of dopamine hydrochloride in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under strict medical supervision.

To order Medopa, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Unlike pure vasoconstrictors, dopamine offers dose‑dependent effects: low doses improve renal blood flow, moderate doses boost cardiac contractility, and high doses raise systemic vascular resistance. This versatility can be advantageous in mixed‑shock states, but selection depends on the clinical scenario and physician preference.

Medopa should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Allow the product to reach room temperature before administration if required by the clinical protocol.

Medopa is given as an intravenous infusion. The solution is added to a compatible IV fluid and infused at a rate set by the clinician, with continuous monitoring of blood pressure, heart rate, and urine output.

Serious risks include myocardial ischemia, severe hypertension, life‑threatening arrhythmias, pulmonary edema, and tissue necrosis at the infusion site. Prompt recognition and management of these events are essential during therapy.

Medopa is contraindicated in patients with known pheochromocytoma, uncorrected tachyarrhythmias, or hypersensitivity to dopamine. Caution is also advised in patients with severe coronary artery disease or uncontrolled hypertension.